Urinary stone disease in pediatric and adult metabolic bone clinic patients.
Andrew L SchwadererAbimbola OduguwaKirsten KusumiPublished in: Urolithiasis (2017)
calcium (48%), vitamin D (40%), bisphosphonates (48%). The majority (75%) were non-ambulatory. Most frequent lithogenic medications: Topiramate (42%) and corticosteroids (27%). This is one of the first studies to consider metabolic bone patients as high risk for urinary stone disease. We found a higher rate of kidney stones in pediatric metabolic bone patients compared to data available for the general pediatric kidney stone population. The most common risk factor for bone and stone disease was nonambulatory status. Males were more frequently affected than females; this is the reverse of general adolescent kidney stone population. The predominance of cerebral palsy and seizure patients can be attributed to their frequency of non-ambulatory status and lithogenic medications such as Topiramate.
Keyphrases
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- blood pressure
- bone mineral density
- primary care
- cerebral palsy
- patient reported outcomes
- mental health
- soft tissue
- big data
- patient reported
- postmenopausal women
- artificial intelligence
- electronic health record
- deep learning
- case control